ESMO 2024 Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments Donwload Press release (PDF) Donwload the Poster (PDF)
Category: Tools-Home
Home news plugin
innovation box
Innovative technologies Push the boundaries of immunotherapy Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network. Discover our myvac® platform Discover our invir.IO® platform
TG4001 box
TG4001 A therapeutic vaccine in Phase II TG4001 targets HPV-induced anogenital cancers. More information
myvac-box
TG4050 One patient, one cancer, one vaccine TG4050 is an individualized neoantigen cancer vaccines from Transgene’s myvac® platform, based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities. TG4050 is being evaluated in a Phase I/II clinical trial. TG4050 video Watch Alessandro Riva presenting first clinical benefits of neoantigen cancer vaccine, TG4050,… Continue reading myvac-box
invirio-box
Oncolytic viruses A new generation of products These innovative multifunctional OVs, from Transgene’s invir.IO® platform, are able to modulate the tumor microenvironment to better attack cancer. Oncolytic viruses video
Presentation
Transgene in a nutshell Download(PDF) Corporate Presentation Download(PDF) Universal Registration Document Download(PDF)
